United States v. Regeneron Pharmaceuticals, Inc.

128 F.4th 324
CourtCourt of Appeals for the First Circuit
DecidedFebruary 18, 2025
Docket23-2086
StatusPublished
Cited by6 cases

This text of 128 F.4th 324 (United States v. Regeneron Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Regeneron Pharmaceuticals, Inc., 128 F.4th 324 (1st Cir. 2025).

Opinion

United States Court of Appeals For the First Circuit

No. 23-2086

UNITED STATES OF AMERICA,

Plaintiff, Appellant,

v.

REGENERON PHARMACEUTICALS, INC.,

Defendant, Appellee.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. F. Dennis Saylor IV, U.S. District Judge]

Before

Montecalvo, Thompson, and Kayatta, Circuit Judges.

Daniel Winik, Attorney, Civil Division, U.S. Department of Justice, with whom Brian M. Boynton, Principal Deputy Assistant Attorney General, Civil Division, U.S. Department of Justice, Joshua S. Levy, Acting U.S. Attorney, District of Massachusetts, Michael S. Raab, Attorney, Civil Division, U.S. Department of Justice, and Charles W. Scarborough, Attorney, Civil Division, U.S. Department of Justice, were on brief, for appellant.

Paul D. Clement, with whom Matthew D. Rowen, Clement & Murphy, PLLC, Theodore V. Wells, Jr., H. Christopher Boehning, Paul Weiss Rifkind Wharton & Garrison LLP, Richard L. Scheff, Katharine Ladd, Faegre Drinker Biddle & Reath LLP, Brien T. O'Connor, John P. Bueker, and Ropes & Gray LLP were on brief, for appellee.

Tara S. Morrissey, Andrew R. Varcoe, U.S. Chamber Litigation Center, Jeffrey S. Bucholtz, Matthew V.H. Noller, and King & Spalding LLP on brief for Chamber of Commerce of the United States of America, amicus curiae.

February 18, 2025 KAYATTA, Circuit Judge. This appeal calls for us to

determine the meaning of the words "resulting from" as used in a

2010 amendment to the federal Anti-Kickback Statute (AKS), 42

U.S.C. § 1320a-7b. See Patient Protection and Affordable Care

Act, Pub. L. No. 111-148, 124 Stat. 119, 759 (2010) (codified at

42 U.S.C. § 1320a-7b(g)). That 2010 amendment states that "a claim

[for payment by a federal healthcare program] that includes items

or services resulting from a violation of [the AKS] constitutes a

false or fraudulent claim for purposes of" the False Claims Act

(FCA), 31 U.S.C. §§ 3729-33. Id. (emphasis added). The FCA, in

turn, imposes civil liability on anyone who "knowingly presents,

or causes to be presented, a false or fraudulent claim for payment

or approval" or "knowingly makes, uses, or causes to be made or

used, a false record or statement material to a false or fraudulent

claim." 31 U.S.C. § 3729(a)(1)(A), (a)(1)(B). Whether a

violation of the AKS is also a false claim under the FCA makes a

difference because the FCA allows both the government and

whistleblowers to bring civil actions for damages.

The government alleges that, in violation of the AKS,

Regeneron Pharmaceuticals knowingly induced prescriptions of a

drug called Eylea by covering copayments for certain patients who

received the drug. Further, contends the government, when doctors

filed Medicare claims for Eylea prescribed to patients receiving

copayment assistance, those claims "resulted from" a violation of

- 3 - the AKS whether or not those claims would have been made even had

Regeneron not covered the co-pay. Accordingly, as the government

sees it, those Medicare claims were "false or fraudulent" for

purposes of the FCA.

Regeneron begs to differ. The company says that a claim

only "result[s] from" an AKS violation if it includes "items or

services" that would not have been paid for by the government

absent the AKS violation. Put differently, Regeneron contends

that an AKS violation must be a but-for cause of the challenged

claim. So, reasons Regeneron, if a doctor would have purchased

(and sought reimbursement for) Eylea anyway, then the subsequent

Medicare claim cannot have "result[ed] from" Regeneron's allegedly

illicit payments. As we will explain, we agree with Regeneron.

I.

A.

Regeneron manufactures Eylea. Eylea is one of just a

few drugs approved by the Food and Drug Administration (FDA) for

treating an ophthalmological condition called neovascular age-

related macular degeneration, also known as wet AMD. Eylea is a

"buy and bill" drug under Medicare Part B. This means that

physicians buy the drug, prescribe it, administer it in their

offices, and then submit a reimbursement claim to Medicare. It

also means that Eylea is subject to Part B's cost-sharing

- 4 - requirement: Medicare covers eighty percent of the cost while the

patient pays the remaining twenty percent.

Eylea is expensive. Since 2013, Medicare Part B has

spent over $11.5 billion on Eylea. A single injection costs

$1,850. Because a patient requires multiple injections per year,

annual per-patient co-pays routinely exceed $2,000. For some

patients, that co-pay can deter the patients from using Eylea.

And while only a few drugs are FDA-approved to treat wet AMD, at

least one other drug that is much cheaper than Eylea is available

for off-label use.

These economics create an incentive for Regeneron to

price Eylea in a way that frees the patient from the co-pay. An

injection that sells for $1,850 with a $330 co-pay will likely

sell less well than an injection that costs $2,000 with no co-pay.

Of course, the insurer -- not the manufacturer -- sets the co-pay

(to ensure that the patient has economic skin in the game when

deciding whether to use the drug). But if the patient knows that

the manufacturer will rebate that co-pay, that is more or less

equivalent to having no co-pay.

Here enters the AKS, which prohibits kickbacks.1 All

parties assume for purposes of this appeal that a rebate by the

1 The AKS imposes criminal liability on anyone who "knowingly and willfully offers or pays any renumeration . . . to any person to induce such person[] . . . to purchase, lease, order . . . or

- 5 - manufacturer to the patient or doctor would be a kickback. So

some creative manufacturers have tried a less direct work-around

by supporting charitable foundations that help patients with co-

pays. The manufacturer gives the foundation a donation, and the

foundation gives patients (or doctors) the co-pay.

Suffice it to say, such an arrangement can easily be

seen as a conduit for manufacturer rebates. The Department of

Health and Human Services therefore issued guidance attempting to

differentiate truly independent co-pay assistance charities from

rebate conduits. See Special Advisory Bulletin: Patient

Assistance Programs for Medicare Part D Enrollees, 70 Fed.

Reg. 70623, 70627 (Nov. 22, 2005).

In this case brought under the FCA, the government

alleges that Regeneron crossed well into the conduit side of that

difference when it paid more than $60 million over the course of

four to five years to the Chronic Disease Fund (CDF), a foundation

that provides copayment assistance to patients suffering from wet

AMD. For purposes of this appeal, we follow the parties' lead by

assuming, without deciding, that some or all of those donations

were unlawful kickbacks. We focus our attention, instead, on the

recommend purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made in whole or in part under a Federal health care program." 42 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
128 F.4th 324, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-regeneron-pharmaceuticals-inc-ca1-2025.